Physician profile
William Kinnebrew
NPI 1831170984
$3,573.83
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $1,214 · 2021: $526.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $390.31 | 2019-2021 | |
| Novo Nordisk INC | $317.53 | 2019-2021 | |
| Pfizer INC. | $314.01 | 2019-2021 | |
| Amarin Pharma, INC. | $245.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $178.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $173.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.69 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.84 | 2019-2020 | |
| Allergan, INC. | $144.95 | 2019-2020 | |
| Lilly USA, LLC | $123.11 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $109.28 | 2019-2021 | |
| Amgen INC. | $73.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $52.68 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $51.32 | 2019 | |
| Daiichi Sankyo INC. | $49.84 | 2019-2021 | |
| Mylan Specialty L.P. | $42.42 | 2019 | |
| Abbvie INC. | $38.39 | 2021 | |
| Astellas Pharma US INC | $26.60 | 2019-2021 | |
| Esperion Therapeutics, INC. | $25.68 | 2021 | |
| Abbott Laboratories | $17.56 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.52 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kinnebrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.